Woodline Partners LP Has $15.60 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Woodline Partners LP lessened its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 0.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 813,647 shares of the company’s stock after selling 5,348 shares during the quarter. Woodline Partners LP’s holdings in Viridian Therapeutics were worth $15,598,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in VRDN. Tang Capital Management LLC lifted its stake in shares of Viridian Therapeutics by 11.1% in the 4th quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company’s stock valued at $47,789,000 after purchasing an additional 250,000 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in Viridian Therapeutics by 90.8% during the fourth quarter. Rafferty Asset Management LLC now owns 172,960 shares of the company’s stock valued at $3,316,000 after buying an additional 82,309 shares in the last quarter. ProShare Advisors LLC raised its holdings in Viridian Therapeutics by 74.1% during the fourth quarter. ProShare Advisors LLC now owns 20,584 shares of the company’s stock valued at $395,000 after buying an additional 8,761 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in shares of Viridian Therapeutics by 155.9% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company’s stock worth $20,850,000 after buying an additional 662,634 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in shares of Viridian Therapeutics by 198.2% during the 4th quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company’s stock worth $13,055,000 after acquiring an additional 452,627 shares in the last quarter.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN opened at $13.66 on Thursday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average is $13.25 and its two-hundred day moving average is $16.99. The company has a market cap of $1.11 billion, a P/E ratio of -3.17 and a beta of 0.57. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.08. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Viridian Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. On average, equities analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on VRDN shares. The Goldman Sachs Group cut their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Royal Bank of Canada cut their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. JMP Securities cut their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.